Cancer clinical trials in the region Île-de-France

684 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05957367 #2024-516476-15-00
Module B Partie 1
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KIT PDGFRA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Deciphera Pharmaceuticals, LLC
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer #NCT06253130 #2023-509230-19
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM BRCA 1/2 CHEK 1/2 PALB2 Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
3 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2 Acute leukemia #NCT04988555
Phase 1, Bras L, M et N
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Acute leukemia #NCT04988555 #2022-502741-10-00
Phase 2, Bras G, H et K
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
MLL fusions NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Acute leukemia #NCT04988555
Phase 2, bras J
Required genetic anomalies
MLL fusions
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Acute leukemia #NCT04988555 #2022-502741-10-00
Phase 2 - Bras I
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1 2 3 or more
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Endometrial cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B3
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd